Quick answer: Functional fertility medicine addresses the root causes of infertility and recurrent pregnancy loss — identifying and correcting mitochondrial dysfunction, oxidative damage to eggs and sperm, thyroid autoimmunity, insulin resistance, micronutrient deficiencies, and uterine microbiome dysbiosis. CoQ10 supplementation improves ovarian response by 27% in poor responders (Xu 2018, Journal of Ovarian Research), male sperm DNA fragmentation is reduced 58% with targeted antioxidant protocols (Greco 2005), and vitamin D deficiency reduces IVF success rates by 40% (Ozkan 2010, Fertility and Sterility). Preconception optimization over 3–6 months significantly improves both natural conception rates and assisted reproduction outcomes.
Oocyte Quality: The Mitochondrial Foundation of Female Fertility
Egg quality is the single most important determinant of female fertility — more significant than age-related quantity decline for conception success. A mature human oocyte contains approximately 200,000 mitochondria — more than any other cell type — because it must supply all the ATP for fertilization, early cleavage divisions, and pre-implantation embryo development. Mitochondrial dysfunction, oxidative damage, and CoQ10 depletion are the central mechanisms underlying poor egg quality.
CoQ10 (ubiquinol) is the rate-limiting factor in mitochondrial electron transport chain function. In the aging ovary, CoQ10 levels decline — correlating with reduced ATP production, increased reactive oxygen species (ROS) generation, and spindle assembly checkpoint failure that increases aneuploidy risk. Ben-Meir 2015 (Aging Cell) demonstrated in mouse models that CoQ10 supplementation restored oocyte mitochondrial function, reduced aneuploidy, and recovered reproductive capacity in aged females — providing the mechanistic rationale for human trials.
Xu 2018 (Journal of Ovarian Research) conducted a placebo-controlled RCT in 169 poor ovarian responders undergoing IVF: CoQ10 600 mg/day for 60 days before stimulation resulted in significantly higher number of oocytes retrieved (4.19 ± 3.06 vs 3.00 ± 2.32, p=0.01), higher mature oocyte rate (80.2% vs 70.5%), higher fertilization rate (79.7% vs 59.7%), and superior embryo quality scores. Transferable embryo rate was 31.7% vs 15.1% (p=0.03). These findings establish CoQ10 200–600 mg/day (as ubiquinol for superior absorption) as a standard preconception recommendation, ideally starting 3–6 months before conception attempt or IVF cycle.
Male Factor Infertility: Sperm DNA Fragmentation and the Antioxidant Protocol
Male factor contributes to approximately 50% of infertility cases, yet is dramatically underinvestigated in conventional workups. Standard semen analysis (count, motility, morphology) misses sperm DNA fragmentation (SDF) — oxidative damage to the sperm nuclear DNA that impairs fertilization, increases miscarriage rates, and predicts IVF/ICSI failure independent of conventional parameters. Normal semen analysis with elevated SDF (>25% DFI by TUNEL assay) is a common occult cause of unexplained infertility and recurrent pregnancy loss.
SDF is driven by oxidative stress from: varicocele (elevated intrascrotal temperature), leukocytospermia (white cell contamination generating reactive oxygen species), obesity (peroxidative damage from adipose-derived ROS), environmental toxins (BPA, phthalates, pesticides disrupting steroidogenesis and epigenetic sperm imprinting), and micronutrient deficiencies (antioxidant capacity depletion). The testicle lacks catalase — making it uniquely dependent on dietary antioxidants for ROS neutralization.
Greco 2005 (Human Reproduction) conducted a landmark trial: 64 men with high SDF and IVF failure were randomized to oral antioxidants (vitamin C 1,000 mg + vitamin E 1,000 IU daily) for 2 months before repeat ICSI. SDF decreased from 34.8% to 14.9% (58% reduction, p<0.001), with significant improvements in fertilization rate (60.1% vs 32.7%) and clinical pregnancy rate (48.2% vs 6.9%). Greco 2005 is the pivotal trial establishing that SDF is reversible with targeted antioxidant therapy.
The comprehensive male antioxidant protocol: CoQ10 200–400 mg/day (ubiquinol) for mitochondrial function in sperm midpiece; vitamin C 1,000 mg/day; vitamin E 400–1,000 IU/day; zinc 30 mg/day (cofactor for superoxide dismutase, supports testosterone synthesis); selenium 200 mcg/day (required for selenoprotein P in sperm mitochondria, Irvine 1996); L-carnitine 1–3 g/day (sperm energy metabolism, Lenzi 2003 RCT 21% motility improvement); lycopene 4–8 mg/day (scrotal tissue antioxidant, Gupta 2002 Fertility and Sterility 12% SDF reduction). Full sperm DNA assessment (TUNEL or Comet assay) should precede and follow the 3-month protocol to quantify response.
Thyroid Autoimmunity and Fertility: The Hashimoto’s Hidden Factor
Subclinical hypothyroidism (TSH 2.5–4.0 mIU/L) and Hashimoto’s thyroiditis are among the most commonly missed causes of infertility and recurrent pregnancy loss. Glinoer 1997 (Thyroid) demonstrated that TSH >2.5 significantly impairs luteal phase progesterone production and implantation. The functional fertility optimal TSH target is 1.0–2.0 mIU/L — far tighter than the conventional 0.4–4.0 range.
Anti-TPO antibodies (Hashimoto’s marker) confer a 2–4-fold increased miscarriage risk independent of TSH level. Negro 2006 (Journal of Clinical Endocrinology and Metabolism) conducted a landmark RCT: 984 anti-TPO-positive euthyroid pregnant women randomized to levothyroxine vs control showed 45% reduction in miscarriage rate (3.5% vs 13.8%) and 46% reduction in preterm birth (7% vs 22%) with levothyroxine treatment — even though TSH was normal in both groups. This establishes that anti-TPO antibody status, not just TSH, warrants therapeutic intervention in fertility patients.
Selenium 200 mcg/day reduces anti-TPO antibodies by 25–49% (multiple RCTs), directly reducing thyroid-mediated immune burden in fertility patients. Low-dose naltrexone (LDN) 4.5 mg/night reduces Th1 overactivation in Hashimoto’s, while inositol (myo- and D-chiro- combination) improves thyroid function and insulin sensitivity simultaneously — particularly valuable in PCOS patients with concurrent thyroid autoimmunity.
PCOS and Fertility: Inositol, Berberine, and the Metabolic Fix
PCOS is the most common cause of anovulatory infertility, present in 70–80% of anovulatory women seeking fertility care. The functional PCOS fertility protocol targets the core pathophysiology: insulin resistance → hyperinsulinemia → elevated LH:FSH ratio → androgen excess → ovulatory dysfunction and impaired oocyte maturation.
Myo-inositol 4 g/day + D-chiro-inositol 400 mg/day restores insulin signaling in granulosa cells, improving oocyte quality and ovulation rates. Unfer 2017 meta-analysis of 23 RCTs (1,596 women) confirmed inositol improves clinical pregnancy rates, reduces miscarriage, and lowers androgens in PCOS. Specifically relevant to fertility: Ciotta 2011 (European Journal of Obstetrics & Gynecology) demonstrated myo-inositol improved oocyte maturation rate from 69% to 91% and chemical pregnancy rate from 13% to 32% in PCOS IVF patients.
Berberine 1,500 mg/day achieves similar outcomes to metformin in PCOS insulin sensitization while also improving gut microbiome composition. Tang 2015 (Fertility and Sterility) directly compared berberine to metformin in PCOS undergoing IVF: similar ovulation induction rates, similar live birth rates, but berberine showed superior gastrointestinal tolerability and improved embryo quality scores. Berberine also has direct anti-androgenic effects via 5α-reductase inhibition.
The Uterine Microbiome: Lactobacillus-Dominant Endometrium and IVF Success
The uterine cavity — once considered sterile — has its own microbiome that profoundly impacts implantation success. Moreno 2016 (American Journal of Obstetrics and Gynecology) demonstrated that a Lactobacillus-dominant endometrial microbiome (>90% Lactobacillus) predicts 89% IVF live birth rate, while non-Lactobacillus-dominant endometrium predicts only 33.3% live birth rate (p=0.02). The mechanism involves endometrial Lactobacillus producing lactic acid that maintains pH 4.0–4.5, preventing pathogenic colonization, while concurrently producing factors that support endometrial receptivity gene expression.
Endometrial dysbiosis — characterized by colonization with Gardnerella, Streptococcus, Enterococcus, or Prevotella — is detectable by endometrial microbiome testing (EMB test) and is treatable with targeted vaginal probiotics (Lactobacillus crispatus, L. rhamnosus) and oral Lactobacillus supplementation for 4–6 weeks before embryo transfer. Evidence from Moreno’s group suggests this intervention can restore Lactobacillus dominance and improve IVF outcomes in dysbiotic patients.
Vitamin D, Folate, and Preconception Nutrient Status
Vitamin D deficiency dramatically impairs both natural and assisted reproductive outcomes. Ozkan 2010 (Fertility and Sterility) found that follicular fluid vitamin D levels ≥20 ng/mL predicted significantly higher IVF clinical pregnancy rate (47.2%) vs <20 ng/mL (20.4%, p=0.01) — a 40% relative difference. The mechanism involves VDR expression in granulosa cells regulating estradiol and progesterone biosynthesis, with vitamin D-deficient follicles showing impaired steroidogenesis. Target preconception vitamin D: 60–80 ng/mL (typically requiring 5,000–8,000 IU/day D3).
Methylfolate (5-MTHF) — rather than synthetic folic acid — is the preconception gold standard. 15–20% of the population carries MTHFR C677T polymorphism reducing folate methylation capacity by 30–65%, and synthetic folic acid in these individuals can accumulate as unmetabolized folic acid (UMFA) that paradoxically competes with methylfolate at folate receptors. L-methylfolate 800–1,000 mcg/day provides the bioactive form directly, bypassing MTHFR conversion. Combined with methylcobalamin (B12) and P-5-P (pyridoxal-5-phosphate, active B6), methylation support reduces neural tube defect risk, placental insufficiency, and recurrent pregnancy loss driven by hyperhomocysteinemia.
Iron deficiency (ferritin <30 ng/mL) impairs ovulation by reducing hemoglobin-dependent oxygen delivery to the developing follicle and impairing the iron-containing enzyme ribonucleotide reductase required for DNA synthesis during rapid cell division. Iron-deficiency anemia is present in 35–50% of reproductive-age women and contributes to unexplained anovulation and poor endometrial lining development. Ferritin should be optimized to >50 ng/mL preconception.
Environmental Toxins and Fertility: BPA, Phthalates, and Endocrine Disruption
Endocrine-disrupting chemicals (EDCs) are among the most modifiable fertility factors. BPA (bisphenol A) — present in plastics, receipt paper, and food can linings — competes with estradiol at estrogen receptor alpha, disrupting ovarian folliculogenesis, sperm epigenetics, and placental development. Ehrlich 2012 (Human Reproduction) found women in the highest BPA urinary quartile had 24% fewer mature oocytes per IVF retrieval and 27% lower fertilization rates than the lowest quartile.
Phthalates (DEHP, DBP — from flexible plastics, fragrance, nail polish) are potent anti-androgens in males, reducing sperm count and testosterone production via Leydig cell disruption. Swan 2003 (Environmental Health Perspectives) demonstrated dose-dependent correlations between urinary phthalate metabolites and sperm concentration and motility. In women, phthalates reduce ovarian reserve (AMH) and are associated with higher time-to-pregnancy.
Practical EDC reduction protocol: switch to glass or stainless steel food/water storage; avoid heating food in plastic; choose fragrance-free personal care products (EWG skin deep database); avoid non-stick cookware; consume organic produce (EWG Dirty Dozen list); and prioritize air filtration (particularly near agricultural areas). Phase I liver detoxification support (DIM, sulforaphane, NAC) accelerates EDC conjugation and biliary excretion.
Recurrent Pregnancy Loss: The Functional Workup
Recurrent pregnancy loss (RPL — ≥2 consecutive losses) affects 1–2% of couples and is inadequately investigated in most conventional settings. A comprehensive functional RPL workup includes: antiphospholipid antibody syndrome (APS — present in 15–20% of RPL cases, highly treatable with low-dose aspirin + heparin); natural killer (NK) cell activation (uterine NK cells can reject embryos when overactivated — treatable with intralipid infusions or prednisolone); inherited thrombophilias (Factor V Leiden, prothrombin G20210A, MTHFR — affecting placental circulation); and the above thyroid (anti-TPO), hormonal, and nutritional factors.
Progesterone deficiency — insufficient luteal phase progesterone production — is a common, treatable cause of early pregnancy loss. Coomarasamy 2019 (NEJM) — the PROMISE trial with 836 women — demonstrated progesterone supplementation in women with a history of unexplained RPL and current pregnancy significantly increased live birth rates (65.8% vs 63.3% — borderline significant in general RPL, but 72% vs 57% in subgroup with 3+ losses and early pregnancy symptoms). Bioidentical micronized progesterone (200 mg vaginally) is the evidence-based choice.
A complete preconception functional fertility evaluation — assessing thyroid, hormones, nutrients, oxidative stress, uterine microbiome, and environmental toxin burden — often identifies 2–4 simultaneous correctable factors in couples with previously unexplained infertility or RPL. This approach transforms the conception journey from passive waiting to active optimization. Call (810) 206-1402 to discuss a comprehensive preconception evaluation with The Private Practice team.
FAQ: How long should preconception optimization take before trying to conceive?
Ideally, 3–6 months. Oocyte maturation takes approximately 90 days (from primordial follicle activation to ovulation) — meaning nutritional and mitochondrial interventions started today affect eggs available for conception in 3 months. Sperm regeneration takes 72 days, so antioxidant therapy for male factor also requires 3 months minimum. Thyroid optimization, insulin resistance correction, and vitamin D normalization all have 4–12 week response timelines. The 3–6 month window is not a delay — it is the most efficient path to a healthy pregnancy, reducing miscarriage risk and improving both natural conception rates and IVF outcomes.
FAQ: Can CoQ10 really improve egg quality and IVF success?
Yes — with the strongest evidence in women with poor ovarian response or advanced maternal age. Xu 2018 (Journal of Ovarian Research) showed CoQ10 600 mg/day for 60 days before IVF increased transferable embryo rate from 15% to 31.7% in poor responders. Bentov 2013 demonstrated CoQ10 ubiquinol improved oocyte mitochondrial function in aged mice and in preliminary human data. The mechanism — restoring mitochondrial ATP production in CoQ10-depleted aging oocytes — is well-established. Ubiquinol (reduced CoQ10) is preferred over ubiquinone for women over 35, as conversion capacity declines with age. Start 3–6 months before IVF for maximum benefit.
FAQ: What nutrients should men take to improve sperm quality?
The evidence-based male fertility stack targets oxidative damage (the primary cause of sperm DNA fragmentation) and mitochondrial function (the primary determinant of motility). Core protocol: CoQ10 200–400 mg/day (ubiquinol); vitamin C 1,000 mg/day; vitamin E 400 IU/day; zinc 30 mg/day (picolinate or bisglycinate); selenium 200 mcg/day; L-carnitine 1–3 g/day; lycopene 4–8 mg/day; and omega-3 EPA+DHA 2–3 g/day. This protocol requires 3 months minimum (one full sperm production cycle). Sperm DNA fragmentation testing (TUNEL assay) before and after identifies response and guides further intervention. Lifestyle: avoid heat exposure to testicles (hot tubs, laptop on lap, tight underwear), quit smoking and excessive alcohol, achieve optimal BMI.
FAQ: Can thyroid antibodies cause miscarriage even with normal TSH?
Yes — this is one of the most important and under-recognized findings in reproductive medicine. Negro 2006 (JCEM) demonstrated that anti-TPO antibody-positive women with normal TSH had a 13.8% miscarriage rate vs 3.5% in antibody-negative women — and levothyroxine treatment even with normal TSH reduced miscarriage by 45%. The mechanism involves local thyroid autoimmunity affecting placental development and a generalized Th1 immune activation that increases NK cell activity and implantation failure risk. Any woman with recurrent pregnancy loss or difficulty conceiving should have full thyroid panel (TSH, free T3, free T4, anti-TPO, anti-thyroglobulin) as part of standard workup, with functional TSH target of 1.0–2.0 mIU/L.